Mazdutide Shows Promise for Fatty Liver Disease by Targeting Cellular Stress and Metabolism
Background
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is a growing global health crisis characterized by excessive fat accumulation in the liver, often leading to inflammation, fibrosis, and potentially liver failure. It is strongly linked to obesity, type 2 diabetes, and metabolic syndrome, with limited effective pharmacological treatments available. This study specifically addresses how Mazdutide, a novel GLP-1/GCGR dual agonist, impacts the underlying cellular and metabolic pathways contributing to MASLD progression.
Results
Treatment with Mazdutide significantly improved MASLD pathology. Hepatic steatosis (fat accumulation) was reduced by 45% compared to untreated MASLD mice, and liver triglyceride levels showed a 38% decrease. Inflammatory markers such as TNF-α and IL-6 in the liver were 55% and 48% lower, respectively (p<0.01 for both). Furthermore, Mazdutide effectively mitigated endoplasmic reticulum (ER) stress, evidenced by a 3.2-fold decrease in GRP78 and CHOP protein expression (p<0.001). This led to a 62% reduction in liver damage markers ALT and AST (p<0.001).
Why It Matters
This study highlights Mazdutide's multifaceted therapeutic potential for MASLD, demonstrating its ability to simultaneously improve lipid metabolism, reduce inflammation, and alleviate cellular stress. The significant improvements observed across multiple MASLD hallmarks suggest that Mazdutide could be a highly effective treatment option. These findings strongly support the advancement of Mazdutide into human clinical trials for MASLD, potentially offering a much-needed pharmacological intervention for this widespread and progressive liver disease. Future research should focus on Phase II and Phase III human trials to confirm efficacy and safety.